Olema Pharmaceuticals, Inc. (OLMA) has 13 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 1 sales totalling $291K. Most recent filing: Sept. 2, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 2, 2026 filed Sept. 1, 2026 | O'Byrne Jason CHIEF FINANCIAL OFFICER | $0 | 650,000 | 0% | No | |
|
|
||||||
| July 27, 2026 filed July 23, 2026 | Harmon Cyrus Director | −$291,163 | 25,000 | −3% | No | |
|
|
||||||
| June 23, 2026 filed June 18, 2026 | BVF PARTNERS L P/IL Director | $0 | 29,500 | 0% | No | |
|
|
||||||
| June 23, 2026 filed June 18, 2026 | Harmon Cyrus Director | $0 | 29,500 | 0% | No | |
|
|
||||||
| June 23, 2026 filed June 18, 2026 | BUTITTA CYNTHIA M Director | $0 | 29,500 | 0% | No | |
|
|
||||||
Showing the 5 most recent of 13 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free